Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Vitamin A for COVID-19: real-time meta analysis of 12 studies
Covid Analysis, October 3, 2022, DRAFT
https://c19early.com/vameta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Rohani (DB RCT) 26% 0.74 [0.31-1.76] hosp. 8/89 11/91 Rohani (DB RCT) 32% 0.68 [0.20-2.33] no recov. 4/89 6/91 Rohani (DB RCT) 80% 0.20 [0.05-0.91] no recov. 2/89 10/91 Rohani (DB RCT) 87% 0.13 [0.03-0.61] no recov. 1/89 8/91 Rohani (DB RCT) 49% 0.51 [0.13-1.98] no recov. 3/89 6/91 Rohani (DB RCT) 63% 0.37 [0.12-1.12] no recov. 4/89 11/91 Rohani (DB RCT) 20% 0.80 [0.31-2.04] no recov. 7/89 9/91 Rohani (DB RCT) 40% 0.60 [0.25-1.45] no recov. 7/89 12/91 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Beigm.. (SB RCT) 89% 0.11 [0.01-1.98] death 0/30 4/30 ICU patients CT​1 Beigm.. (SB RCT) 41% 0.59 [0.17-1.28] hosp. 4/30 16/30 ICU patients CT​1 Beigm.. (SB RCT) 45% 0.55 [0.38-0.78] SOFA 30 (n) 30 (n) ICU patients CT​1 Elkazzaz (RCT) 86% 0.14 [0.01-2.60] death 0/20 3/20 Elkazzaz (RCT) 67% 0.33 [0.08-1.46] ICU 2/20 6/20 Elkazzaz (RCT) 35% 0.65 [0.55-0.76] recov. time 20 (n) 20 (n) Elkazzaz (RCT) 44% 0.56 [0.48-0.65] viral time 20 (n) 20 (n) Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Nimer 21% 0.79 [0.45-1.35] hosp. 15/144 204/2,004 Nimer 21% 0.79 [0.46-1.30] severe case 17/144 243/2,004 vitamin A COVID-19 outcomes c19early.com/va Oct 2022 1 CT: study uses combined treatment Favors vitamin A Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit